Table 2.
Complexation of various anticancer drugs with cyclodextrin and their derivatives.
| Serial number | Drug | Use | Cyclodextrin | Method | Outcome | Reference |
|---|---|---|---|---|---|---|
| 1 | 9-Nitro camptothecin | Pancreatic cancer | HP-β-CD | Colyophilization | Significant improvement in antitumor activity and reduction in toxicity | [45] |
|
| ||||||
| 2 | Methotrexate | Melanoma |
β-CD HP β-CD |
Neutralization | Enhancement of aqueous solubility and bioavailability | [46] |
|
| ||||||
| 3 | Lonidamine | Prostate cancer | PM-β-CD | Physical mixture | Enhancement of solubility | [47] |
|
| ||||||
| 4 | Exemestane | Breast cancer | M β-CD | Kneading | Increase in solubility, improvement in bioavailability and dissolution | [48] |
|
| ||||||
| 5 | Vorinostat | Lymphoma | HP-β-CD, RM β-CD |
Freeze-drying | Enhancement of bioavailability | [49] |
|
| ||||||
| 6 | Imatinib | Chronic leukemia |
β-CD, RM β-CD |
Freeze-drying | Enhancement of solubility | [50] |
|
| ||||||
| 7 | Doxorubicin | Lymphoma and leukemia | HP β-CD | Freeze-drying | Stability to acid hydrolysis and photodegradation | [51] |
|
| ||||||
| 8 | Cisplatin | testicular, ovarian, and cervical carcinoma | HP-β-CD | Freeze-drying and physical mixture | Increase in solubility, improvement in dissolution rate, and reduction of toxicity | [52] |
|
| ||||||
| 9 | Flutamide | Prostatic carcinoma |
β-CD, HP-β-CD |
Lyophilization | Enhancement of solubility and dissolution | [53] |
|
| ||||||
| 10 | Zerumbone | Colon and skin cancer | HP-β-CD | Freeze-drying | Improvement in solubility, stability, and bioavailability | [54] |
|
| ||||||
| 11 | Melphalan | Multiple myeloma and ovarian cancer | HP-β-CD | Freeze-drying | Stability against hydrolysis, solubility enhancement | [55] |
|
| ||||||
| 12 | Oridonin | Esophageal and cardiac cancer | β-CD | Freeze-drying | Enhancement of bioavailability | [56] |
|
| ||||||
| 13 | 5-Fluorouracil | Cervical cancer |
β-CD, HP β-CD |
Colyophilization | Enhancement of solubility | [57] |